← Back
Data updated: Mar 10, 2026
CYTOKINETICS
Cardiovascular
CYTOKINETICS is a pharmaceutical company focused on Cardiovascular. Key products include MYQORZO.
2025
Since
1
Drugs
-
Trials
2
Approved (2yr)
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 100%
0 drugs Phase 3: 4 Phase 2: 2
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-12-19
- Latest
- 2026-02-05
- Applications
- 1